Cigna Group's Evernorth health services announced a $100 million investment on Wednesday to develop an artificial intelligence-powered pharmacy program. This initiative aims to enhance patient access to specialty care by improving the efficiency of prescription processing and service responsiveness, according to the company. The investment will be allocated through 2028, focusing on the launch of the 'Pharmacy Forward' program with its Accredo Specialty Pharmacy.
Key Details
Specialty drugs currently account for over half of total prescription spending managed by health plans, employers, and government programs. Cigna stated that employer clients report specialty costs can represent 60% or more of their total drug expenditures. Katya Andresen, Chief Data, Digital and AI Officer at Cigna, emphasized that the integration of real-time data and advanced analytics will allow for more personalized and proactive patient support. This approach aims to reduce prescription processing timelines and enhance overall health outcomes.
The new program will initially serve patients with chronic and complex conditions through condition-specific Therapeutic Resource Centers. Evernorth and Cigna executives noted that over 90% of patients will be within a 'same/next-day ground shipping' radius, ensuring timely delivery of medications.
Background
Cigna's investment comes amid a growing demand for specialty drugs, particularly anti-obesity medications, which have gained popularity for their weight loss benefits. This trend underscores the need for improved systems to manage the complexities of specialty drug care.
Related coverage: Summer Travel Costs Surge 17% as Demand Peaks in July.
Sources: forbes.com, forbes.com.
Cigna's investment is likely to affect the healthcare sector, particularly companies involved in specialty pharmaceuticals and pharmacy services, as it may lead to increased competition and innovation in patient care delivery. Investors will watch for further developments in the rollout of the 'Pharmacy Forward' program and its impact on specialty drug costs.